Inactivation of the cyclin-dependent kinase inhibitor p 16(INK4a) (CDKN2/MTS1) is documented in a wide variety of cancer cell lines and tumors. We have shown that loss of p16(INK4a) protein expression is a common event in early stage non-small cell lung cancer (NSCLC), correlates with a significantly worse survival, and is more common in higher stage disease. One hundred NSCLC tumors from patients undergoing definitive thoracotomies at a single institution were examined for p16(INK4a) and retinoblastoma protein (pRB) expression. Abnormal pRB staining was identified in 15% of the tumors, whereas 51% possessed aberrant p16(INK4a) protein expression. Tumors with aberrant expression of p16(INK4a) by immunohistochemistry were associated with a significantly worse survival (P = 0.04). Additionally, the inverse correlation of pRB and p16(INK4a) expression previously noted in lung cancer cell lines and tumors was confirmed in this large cohort of patients, with 65% of the tumors demonstrating inverse expression of pRB and p16(INK4a) (P = 0.00019). A statistically significant increase in aberrant p16(INK4a) expression, as well as inverse expression of p16(INK4a) and pRB, was seen with increasing pathological stage of disease. These findings establish the prognostic significance of the absence of p16(INK4a) in resected NSCLC and confirm the critical importance of disrupting the pathway of cyclin-dependent kinase-mediated phosphorylation of pRB in the molecular oncogenesis and progression of NSCLC.
|Original language||English (US)|
|Number of pages||6|
|State||Published - Aug 1 1996|